MedBiome, a company specializing in the development of therapeutics targeting the gut microbiome, today announced that Dr. Shane Climie has been appointed as Vice-President of Business Development.
In Dr. Climie’s role as Vice President of Business Development at MedBiome Inc. he is responsible for corporate development, strategy and partnering. Dr. Climie is also President of Shane Climie & Associates which is focused on the provision of consulting services to life science companies. He is a Principal with Popper and Company, which is focused on building life science organizations by meeting the needs of entrepreneurial, life science startups and the investors that support those early stage organizations. Dr. Climie also serves as Vice President of Corporate Development at Cyclica Inc. where he supports company growth by managing corporate relationships and strategic planning. Dr. Climie has more than 25 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Dr. Climie has been a Principal at Popper and Company for 13 years where he has provided interim executive management services to early-stage biotechnology companies in the areas of diagnostics and drug discovery / drug development as well as support in the areas of business management, marketing strategy and technology or opportunity assessment. Prior to his current appointments, Dr. Climie held several positions at Protana (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice President of Research Collaborations, and Vice President of Proteomics and Business Development. Dr. Climie was also co-founder, Vice President and Chief Technology Officer of MDS Ocata and was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. Prior to that, Dr. Climie held several managerial positions at Allelix Biopharmaceuticals, Inc. including Principal Scientist. Dr. Climie completed postdoctoral work at the University of California at San Francisco and received a Ph.D. in Medical Biophysics from the University of Toronto.
“We are delighted that Dr. Shane Climie joined MedBiome. His outstanding experience in business strategy and business development in the biotechnology industry will benefit MedBiome ,” commented Dr. Daniel Figeys, President of MedBiome.